SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Amish A. Patel, Matthew J. Budoff, Coronary Artery Disease in Patients with HIV Infection, American Journal of Cardiovascular Drugs, 2015,

    CrossRef

  2. 2
    M. T. May, S. M. Ingle, D. Costagliola, A. C. Justice, F. de Wolf, M. Cavassini, A. D'Arminio Monforte, J. Casabona, R. S. Hogg, A. Mocroft, F. C. Lampe, F. Dabis, G. Fatkenheuer, T. R. Sterling, J. del Amo, M. J. Gill, H. M. Crane, M. S. Saag, J. Guest, H.-R. Brodt, J. A. Sterne, Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC), International Journal of Epidemiology, 2014, 43, 3, 691

    CrossRef

  3. 3
    Inge Petersen, Lara Fairall, Catherine O. Egbe, Arvin Bhana, Optimizing lay counsellor services for chronic care in South Africa: A qualitative systematic review, Patient Education and Counseling, 2014, 95, 2, 201

    CrossRef

  4. 4
    Jureeporn Jantarapakde, Nittaya Phanuphak, Chintana Chaturawit, Supabhorn Pengnonyang, Pornpen Mathajittiphan, Piyaporn Takamtha, Narunat Dungjun, Suteeraporn Pinyakorn, Warabhorn Pima, Wisit Prasithsirikul, Praphan Phanuphak, Prevalence of Metabolic Syndrome Among Antiretroviral-Naive and Antiretroviral-Experienced HIV-1 Infected Thai Adults, AIDS Patient Care and STDs, 2014, 28, 7, 331

    CrossRef

  5. 5
    Franck Boccara, Sylvie Lang, Catherine Meuleman, Stephane Ederhy, Murielle Mary-Krause, Dominique Costagliola, Jacqueline Capeau, Ariel Cohen, HIV and Coronary Heart Disease, Journal of the American College of Cardiology, 2013, 61, 5, 511

    CrossRef

  6. 6
    Karin K. Pedersen, Maria Pedersen, Marius Trøseid, Julie C. Gaardbo, Tamara T. Lund, Carsten Thomsen, Jan Gerstoft, Dag Kvale, Susanne D. Nielsen, Microbial Translocation in HIV Infection Is Associated With Dyslipidemia, Insulin Resistance, and Risk of Myocardial Infarction, JAIDS Journal of Acquired Immune Deficiency Syndromes, 2013, 64, 5, 425

    CrossRef

  7. 7
    Yukiona Y.T. Yeung, Shui-Shan Lee, Paul M. Vanhoutte, Susan W.S. Leung, Prolonged Exposure to Lopinavir Impairs Endothelium-dependent Hyperpolarization-mediated Relaxation in Rat Mesenteric Arteries, Journal of Cardiovascular Pharmacology, 2013, 62, 4, 397

    CrossRef

  8. 8
    Sandra C. Fuchs, Paulo R. Alencastro, Maria Letícia R. Ikeda, Nêmora T. Barcellos, Fernando H. Wolff, Ajácio B. M. Brandão, Ricardo A. A. Ximenes, Demócrito de B. Miranda-Filho, Heloísa Ramos Lacerda, Maria de Fátima P. M. de Albuquerque, Ulisses Ramos Montarroyos, Max W. Nery, Marilia D. Turchi, Risk of Coronary Heart Disease among HIV-Infected Patients: A Multicenter Study in Brazil, The Scientific World Journal, 2013, 2013, 1

    CrossRef

  9. 9
    M. T. May, R. S. Hogg, A. C. Justice, B. E. Shepherd, D. Costagliola, B. Ledergerber, R. Thiebaut, M. J. Gill, O. Kirk, A. van Sighem, M. S. Saag, G. Navarro, P. Sobrino-Vegas, F. Lampe, S. Ingle, J. L. Guest, H. M. Crane, A. D'Arminio Monforte, J. J. Vehreschild, J. A. Sterne, Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics, International Journal of Epidemiology, 2012, 41, 6, 1807

    CrossRef

  10. 10
    S. Lang, M. Mary-Krause, A. Simon, M. Partisani, J. Gilquin, L. Cotte, F. Boccara, D. Costagliola, HIV Replication and Immune Status Are Independent Predictors of the Risk of Myocardial Infarction in HIV-Infected Individuals, Clinical Infectious Diseases, 2012, 55, 4, 600

    CrossRef

  11. 11
    N Edwards-Jackson, SJ Kerr, HV Tieu, J Ananworanich, SM Hammer, K Ruxrungtham, P Phanuphak, A Avihingsanon, Cardiovascular risk assessment in persons with HIV infection in the developing world: comparing three risk equations in a cohort of HIV-infected Thais, HIV Medicine, 2011, 12, 8
  12. 12
    A. J. Leigh Brown, S. J. Lycett, L. Weinert, G. J. Hughes, E. Fearnhill, D. T. Dunn, Transmission Network Parameters Estimated From HIV Sequences for a Nationwide Epidemic, Journal of Infectious Diseases, 2011, 204, 9, 1463

    CrossRef

  13. 13
    Jasmine Malek, Robert Rogers, Joseph Kufera, Jon Mark Hirshon, Venous thromboembolic disease in the HIV-infected patient, The American Journal of Emergency Medicine, 2011, 29, 3, 278

    CrossRef

  14. 14
    M. Aboud, A. Elgalib, L. Pomeroy, G. Panayiotakopoulos, E. Skopelitis, R. Kulasegaram, C. Dimian, F. C Lampe, A. Duncan, A. S. Wierzbicki, B. S. Peters, Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study, International Journal of Clinical Practice, 2010, 64, 9
  15. 15
    R Barry, How does vascular disease associated with retroviral infection differ from atherosclerosis?, Southern African Journal of Anaesthesia and Analgesia, 2010, 16, 1, 51

    CrossRef

  16. 16
    John M Kaldor, Valerie Delpech, Rebecca J Guy, AIDS case reporting: do we still need it?, The Lancet, 2009, 373, 9658, 181

    CrossRef

  17. 17
    Sebastián Hernández, Magdalena Vidal, Enric Pedrol, Evaluación del riesgo cardiovascular e intervención en los pacientes con VIH, Enfermedades Infecciosas y Microbiología Clínica, 2009, 27, 40

    CrossRef

  18. 18
    S Collot-Teixeira, F De Lorenzo, L Waters, C Fletcher, D Back, S Mandalia, A Pozniak, S Yilmaz, JL McGregor, B Gazzard, M Boffito, Impact of Different Low-Dose Ritonavir Regimens on Lipids, CD36, and Adipophilin Expression, Clinical Pharmacology & Therapeutics, 2009, 85, 4
  19. 19
    L. Vandekerckhove, C. Verhofstede, D. Vogelaers, Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients, Journal of Antimicrobial Chemotherapy, 2009, 63, 6, 1087

    CrossRef

  20. 20
    V. Cooper, G. Gellaitry, M. Hankins, M. Fisher, R. Horne, The influence of symptom experiences and attributions on adherence to highly active anti-retroviral therapy (HAART): a six-month prospective, follow-up study, AIDS Care, 2009, 21, 4, 520

    CrossRef

  21. 21
    S. Badiou, R. Thiebaut, V. Aurillac-Lavignolle, F. Dabis, F. Laporte, J.P. Cristol, P. Mercie, Association of non-HDL cholesterol with subclinical atherosclerosis in HIV-positive patients, Journal of Infection, 2008, 57, 1, 47

    CrossRef

  22. 22
    M Colafigli, S Di Giambenedetto, L Bracciale, E Tamburrini, R Cauda, A De Luca, Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen, HIV Medicine, 2008, 9, 3
  23. 23
    J. E. Mallewa, E. Wilkins, J. Vilar, M. Mallewa, D. Doran, D. Back, M. Pirmohamed, HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options, Journal of Antimicrobial Chemotherapy, 2008, 62, 4, 648

    CrossRef

  24. 24
    M Youle, M Osio, A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl l-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection, HIV Medicine, 2007, 8, 4
  25. 25
    R. C. Kaplan, L. A. Kingsley, A. R. Sharrett, X. Li, J. Lazar, P. C. Tien, W. J. Mack, M. H. Cohen, L. Jacobson, S. J. Gange, Ten-Year Predicted Coronary Heart Disease Risk in HIV-Infected Men and Women, Clinical Infectious Diseases, 2007, 45, 8, 1074

    CrossRef

  26. 26
    Matthew G Law, Cardiovascular complications of HIV: an overview of risk and a novel approach to prevention ??? the HIV polypill study, Current Opinion in HIV and AIDS, 2006, 1, 6, 482

    CrossRef

  27. 27
    CL Cooper, Evaluation of nevirapine-switch strategies for HIV treatment, HIV Medicine, 2006, 7, 8
  28. 28
    M. Bower, T. Powles, M. Nelson, S. Mandalia, B. Gazzard, J. Stebbing, Highly Active Antiretroviral Therapy and Human Immunodeficiency Virus-Associated Primary Cerebral Lymphoma, JNCI Journal of the National Cancer Institute, 2006, 98, 15, 1088

    CrossRef

  29. 29
    Stacy D. Fisher, Tracie L. Miller, Steven E. Lipshultz, Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis, Atherosclerosis, 2006, 185, 1, 1

    CrossRef

  30. 30
    Maria Cristina Uccelli, Carlo Torti, Giuseppe Lapadula, Lorena Labate, Giuliana Cologni, Valeria Tirelli, Francesca Moretti, Silvia Costarelli, Eugenia Quiros-Roldan, Giampiero Carosi, Influence of Folate Serum Concentration on Plasma Homocysteine Levels in HIV-Positive Patients Exposed to Protease Inhibitors Undergoing HAART, Annals of Nutrition and Metabolism, 2006, 50, 3, 247

    CrossRef

  31. 31
    TR Glass, C Ungsedhapand, M Wolbers, R Weber, PL Vernazza, M Rickenbach, H Furrer, E Bernasconi, M Cavassini, B Hirschel, M Battegay, HC Bucher, Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study, HIV Medicine, 2006, 7, 6
  32. 32
    H Curtis, MA Johnson, G Brook, Re-audit of patients initiating antiretroviral therapy, HIV Medicine, 2006, 7, 7
  33. 33
    MG Law, N Friis-Møller, WM El-Sadr, R Weber, P Reiss, A D'Arminio Monforte, R Thiébaut, L Morfeldt, S De Wit, C Pradier, G Calvo, O Kirk, CA Sabin, AN Phillips, JD Lundgren, The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study, HIV Medicine, 2006, 7, 4
  34. 34
    N. Lohse, G. Kronborg, J. Gerstoft, C. S. Larsen, G. Pedersen, C. Pedersen, H. T. Sorensen, N. Obel, Virological Control during the First 6-18 Months after Initiating Highly Active Antiretroviral Therapy as a Predictor for Outcome in HIV-Infected Patients: A Danish, Population-Based, 6-Year Follow-Up Study, Clinical Infectious Diseases, 2006, 42, 1, 136

    CrossRef

  35. 35
    Shabbar Jaffar, Thilo Govender, Anupam Garrib, Tanya Welz, Heiner Grosskurth, Peter G. Smith, Hilton Whittle, Michael L. Bennish, Antiretroviral treatment in resource-poor settings: public health research priorities, Tropical Medicine & International Health, 2005, 10, 4
  36. 36
    B Gazzard, British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005), HIV Medicine, 2005, 6, S2
  37. 37
    F. Patrick Robinson, Julie Anne Hoff, George T. Kondos, Coronary Artery Calcium in HIV-infected Men Treated With Highly Active Antiretroviral Therapy, The Journal of Cardiovascular Nursing, 2005, 20, 3, 149

    CrossRef

  38. 38
    R Jones, S Sawleshwarkar, C Michailidis, A Jackson, S Mandalia, J Stebbing, M Bower, M Nelson, BG Gazzard, GJ Moyle, Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone, HIV Medicine, 2005, 6, 6
  39. 39
    Steven A. Grover, Louis Coupal, Norbert Gilmore, Jayanti Mukherjee, Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy, The American Journal of Cardiology, 2005, 95, 5, 586

    CrossRef

  40. 40
    Martin Stürmer, Annemarie Berger, Wolfgang Preiser, Hans Wilhelm Doerr, Kommerzielle Systeme zur Genotypisierung von humanen Immundefizienzviren Typ 1: Vergleich von ViroSeq (Abbott) und TruGene (Bayer). Commercially available assays for genotyping of human immunodeficiency virus type 1: Comparison of ViroSeq (Abbott) and TruGene (Bayer), LaboratoriumsMedizin, 2005, 29, 1, 50

    CrossRef

  41. 41
    Lukas E. Spieker, Bilgehan Karadag, Christian Binggeli, Roberto Corti, Rapid progression of atherosclerotic coronary artery disease in patients with human immunodeficiency virus infection, Heart and Vessels, 2005, 20, 4, 171

    CrossRef

  42. 42
    J. Montaner, M. Harris, R. Hogg, Structured Treatment Interruptions: A Risky Business, Clinical Infectious Diseases, 2005, 40, 4, 601

    CrossRef

  43. 43
    Oriol Manuel, Rodolphe Thiébaut, Roger Darioli, Philip E Tarr, Treatment of dyslipidaemia in HIV-infected persons, Expert Opinion on Pharmacotherapy, 2005, 6, 10, 1619

    CrossRef

  44. 44
    Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe, AIDS, 2004, 18, 10, 1443

    CrossRef

  45. 45
    Christa Claes, Johann-Matthias Graf von der Schulenburg, Matthias Stoll, Cost-effectiveness of managing HIV infection, Expert Review of Pharmacoeconomics & Outcomes Research, 2004, 4, 1, 79

    CrossRef

  46. 46
    P. L. Anderson, T. N. Kakuda, K. A. Lichtenstein, Reply to Stevens et al, Clinical Infectious Diseases, 2004, 39, 6, 878

    CrossRef

  47. 47
    Nina Friis-Møller, Rainer Weber, Peter Reiss, Rodolphe Thiébaut, Ole Kirk, Antonella d'Arminio Monforte, Christian Pradier, Linda Morfeldt, Silvia Mateu, Matthew Law, Wafaa El-Sadr, Stephan De Wit, Caroline A Sabin, Andrew N Phillips, Jens D Lundgren, Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study, AIDS, 2003, 17, 8, 1179

    CrossRef

  48. 48
    Combination Antiretroviral Therapy and the Risk of Myocardial Infarction, New England Journal of Medicine, 2003, 349, 21, 1993

    CrossRef

  49. 49
    Judith S. Currier, Anne Taylor, Felicity Boyd, Christopher M. Dezii, Hugh Kawabata, Beth Burtcel, Jen-Fue Maa, Sally Hodder, Coronary Heart Disease in HIV-Infected Individuals, JAIDS Journal of Acquired Immune Deficiency Syndromes, 2003, 33, 4, 506

    CrossRef

  50. 50
    Jens D. Lundgren, Dyslipidaemia and cardiovascular disease risk associated with antiretroviral drugs, Pharmacoepidemiology and Drug Safety, 2003, 12, 5
  51. 51
    James J. Kohler, William Lewis, Cardiovascular Toxicities of Life-Saving Drugs: Antiviral Therapy,